Table 2
Characteristics of patients according to the rate of cognitive decline on the mini-mental state examination and effect of lipid lowering agents on the progression of cognitive decline
| Variable | Frequency (%) | Odds ratio | 95% CI | p Value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Slow cognitive progression (<1.8 point/year) (n = 172) | Fast cognitive progression (>1.8 point/year) (n = 170) | |||||||||
| AChEI, acetyl choline esterase inhibitor; DRS, dementia rating scale26; LLA, lipid lowering agent; NA, not available; NSAID, non-steroidal anti-inflammatory drug; SSRI, selective serotonin reuptake inhibitor. | ||||||||||
| Qualitative | ||||||||||
| Men | 51 (29.7) | 59 (34.7) | 1.26 | 0.80 to 1.99 | 0.317 | |||||
| Arterial hypertension | 97 (56.4) | 100 (58.8) | 1.10 | 0.72 to 1.70 | 0.650 | |||||
| Diabetes mellitus | 34 (19.8) | 22 (12.9) | 0.60 | 0.34 to 1.08 | 0.088 | |||||
| Antidepressant (SSRI) | 73 (42.4) | 85 (50) | 1.36 | 0.88 to 2.08 | 0.161 | |||||
| AChEI at entry | 138 (80.2) | 141 (82.9) | 1.20 | 0.69 to 2.08 | 0.518 | |||||
| Treatment with AChEI at the end of follow up | 120 (69.8), NA = 12 | 111 (65.3) NA = 11 | 0.77 | 0.47 to 1.26 | 0.094 | |||||
| NSAIDs | 81 (47.1) | 80 (47.1) | 1.00 | 0.65 to 1.53 | 0.995 | |||||
| Vascular lesion on imaging | 45 (26.2) | 40 (23.5) | 0.87 | 0.53 to 1.42 | 0.573 | |||||
| Education <8 years | 139 (80.8) | 129 (76.3) NA = 1 | 0.77 | 0.45 to 1.29 | 0.488 | |||||
| Education 8–12 years | 19 (11) | 26 (15.4) NA = 1 | 1.46 | 0.77 to 2.77 | ||||||
| Education >12 years | 14 (8.1) | 14 (8.3) NA = 1 | 1.02 | 0.47 to 2.21 | ||||||
| Lipid lowering agents | 79 (45.9) | 50 (29.4) | 0.49 | 0.31 to 0.77 | 0.002 | |||||
| Fibrates | 39 (22.7) | 24 (14.1) | 0.56 | 0.32 to 0.98 | 0.041 | |||||
| Statins | 37 (21.5) | 24 (14.1) | 0.60 | 0.34 to 1.06 | 0.074 | |||||
| Others hypolipaemic agents | 18 (10.5) | 14 (8.2) | 0.77 | 0.37 to 1.60 | 0.479 | |||||
| Hypercholesterolaemia | 114 (66.3) | 99 (58.2) | 1.41 | 0.91 to 2.19 | 0.125 | |||||
| Quantitative (mean (SD)) | ||||||||||
| Total duration of LLAs (months) | 49.9 (50), NA = 6 | 32.3 (29.2), NA = 4 | 0.033 | |||||||
